// App-Quantinova.ai

: Excellent Response to Blinatumomab in Children and Young Adults with Refractory B Lineage Acute Lymphoblastic Leukaemia for Persistent MRD or after Debulking Chemotherapy for Higher Disease Burden

Researchers

Presenter

  • Vasudha Rao

Principal Investigators

  • Katherine Clesham

  • Jack Luke Bartram

  • Phil Ancliff

  • Sara Ghorashian

  • David O'Connor

  • Vesna Pavasovic

  • Anupama Rao

  • Sujith Samarasinghe

  • Carole Cairns

  • David Marks

  • David Taussig

  • Ajay Vora

Medical Centers

  • Great Ormond Street Hospital, London, United Kingdom

  • Royal Hospital for Sick Children, Glasgow, United Kingdom

  • University of Bristol, Bristol, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Down syndrome

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 19

Drug/Treatment

  • Blinatumomab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved